Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2004-07-28 | Michael Weiser, M.D., Ph.D., has been a director of the Company since the completion of the Company's merger transaction with Manhattan Research Development, Inc. in February 2003. He served as a director of Manhattan Research Development since December 2001 and as its Chief Medical Officer from its inception until August 2001. Dr. Weiser provides services to the Company pursuant to a consulting agreement dated March 1, 2003. The consulting agreement provides that Dr. Weiser will provide scientific advisory services to the Company in the areas of obesity and drug delivery. The Company is required to pay to Dr. Weiser $6,250 per month during the term of the consulting agreement. |
| 2005-10-21 | Michael Weiser, M.D., Ph.D., has been a director of the Company since the completion of the Company’s merger transaction with Manhattan Research Development, Inc. in February 2003. Dr. Weiser is also a member of Orion Biomedical GP, LLC, and serves on the board of directors of several privately held companies. Dr. Weiser also serves as a director of VioQuest Pharmaceuticals, Inc. (OTCBB: VQPH) since February 2003 and Hana Biosciences, Inc. (AMX: HBX) since July 2004. The Compensation Committee is currently comprised of Messrs. Steinhart, Hoenlein, Herskowitz and Dr. Weiser. |
| 2006-11-17 | Michael Weiser, M.D., Ph.D., a director of Manhattan since February 2003, is Director of Research of Paramount BioCapital, Inc. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University medical College and received his M.D. from New York University School of Medicine, where he also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience. Dr. Weiser currently serves on the boards of directors of Hana Biosciences, Inc. (NASDAQ: HNAB), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Emisphere Technologies Inc. (Nasdaq: EMIS), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) and VioQuest Pharmaceuticals Inc. (OTCBB: VQPH), as well as several other privately held biotechnology companies. |
| 2007-04-30 | Michael Weiser, M.D., a director of Manhattan since February 2003, ... The Board of Directors has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership for each of the Board committees: Compensation Committee Messrs. Herskowitz, Hoenlein, Steinhart and Dr. Weiser ... The following table shows the compensation earned by each of our non-employee directors for the year ended December 31, 2006: Michael Weiser Fees Earned or Paid in Cash $3,000 Option Awards $38,328 All Other Compensation $0 Total $41,328 |
| 2008-05-12 | Michael Weiser, M.D., Ph.D., has served as a director of Manhattan since February 2003. ... Compensation Committee members: Messrs. Herskowitz, Hoenlein, Steinhart and Weiser (Chair). ... The following table shows the compensation earned by each of our non-employee directors for the year ended December 31, 2007: Michael Weiser total compensation $32,448. |
| 2009-10-29 | Michael Weiser, M.D., Ph.D., has served as a director of Manhattan since February 2003. ... The following table shows the compensation earned by each of our non-employee directors for the year ended December 31, 2008: Michael Weiser (6) $5,500 $14,767 - $20,267 ... Compensation Committee: Messrs. McInerney, Steinhart and Dr. Weiser (Chair) |
Data sourced from SEC filings. Last updated: 2026-02-03